Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 21, 2013; DOI: 10.1158/0008-5472.CAN-11-
INTRODUCTION
Pancreatic cancer is the fourth leading cause of cancer-related death and is characterized by early metastasis and resistance to chemotherapy and irradiation. The identification of deregulated molecular pathways in pancreatic cancer and the development of novel targeted therapies had so far little impact on clinical outcome (1) . Prognosis of patients with pancreatic cancer has remained extremely poor with a 5-year survival rate of less than 5%. A key event in tumor progression of pancreatic cancer is deregulation of TGF-β signaling (2) . Under normal conditions, TGF-β maintains tissue homeostasis by controlling cellular proliferation, differentiation, survival and cell adhesion. Deregulated TGF-β signaling allows tumors to usurp homeostatic effects for promoting tumor growth, invasion, metastasis, and tumor angiogenesis (2) . Moreover, TGF-β has immunosuppressive effects such as inhibition of cytotoxic T cells and NK cells, induction of FoxP3 + regulatory T cells, and shifting antigen-presenting cell function towards tolerance (3, 4) . Both tumor cells and immune cells, such as regulatory T cells and myeloid-derived suppressor cells (MDSC), contribute to enhanced TGF-β production in cancer patients. Elevated TGF-β levels in serum and tumors correlate with poor prognosis in tumor patients (5, 6) . Thus, TGF-β has generated interest as a target for novel anti-cancer agents. Anti-TGF-β compounds have shown efficacy in preclinical studies and some of these have moved into clinical investigation for melanoma, brain tumors, colorectal, renal and pancreatic cancer (7) (8) (9) (10) (11) .
Tumor infiltration with T cells represents a positive prognostic factor for pancreatic carcinoma, indicating that immune surveillance may occur despite locally active immunosuppressive mechanisms (12) . However, tumor-infiltrating T cells frequently lack effector function due to the hostile tumor microenvironment, which is enriched with immunosuppressive factors. Identifying targets and compounds for immune activation is thus of utmost importance for effective immunotherapy. In this respect, in addition to TGF-β inhibition, Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 21, 2013; DOI: 10.1158/0008-5472.CAN- activation of innate immune effector mechanisms via pattern recognition receptors is a promising strategy for breaking tumor-mediated immunosuppression (13) . suggests that RIG-I may represent a novel target for cancer immunotherapy (14, 15) . RIG-I is a cytosolic sensor of viral RNA detecting a triphosphate group at the 5'-end generated by viral RNA polymerases (16, 17) . Upon activation, RIG-I initiates a signaling cascade mediated by IRF-3, IRF-7, and NF-κB, leading to an anti-viral response program characterized by the production of type I IFN (IFN-α and IFN-β) and other innate immune response genes, such as the chemokine CXCL10 (18). Moreover, RIG-I signaling induces apoptosis in susceptible cells. In vitro transcribed 5'-triphosphate RNA (ppp-RNA) can be applied as RIG-I ligand to trigger pro-apoptotic signaling via the intrinsic mitochondrial pathway (14, 15) . Of note, RIG-I-mediated apoptosis occurs predominantly in tumor cells, as non-malignant cells are protected from proapoptotic signaling via Bcl-x L (14) .
The novel ppp-siRNA strategy offers the advantage of combining RIG-I-mediated immune activation with RNAi-mediated gene silencing within a single molecule. In the study by Poeck et al. a bifunctional ppp-siRNA silencing the anti-apoptotic molecule Bcl-2 resulted in efficient tumor cell apoptosis in melanoma (15) . To date, little is known about RIG-I expression in other cancer types. We hypothesized that dual targeting of immune suppression via RIG-I activation and TGF-β silencing promotes efficacy against pancreatic cancer. We studied RIG-I expression and signaling in human pancreatic carcinoma cell lines. In addition, the therapeutic 6 efficacy of a bifunctional ppp-siRNA combining ppp-RNA-mediated RIG-I signaling with siRNA-mediated TGF-β silencing was assessed in the aggressive Panc02 mouse model of pancreatic carcinoma. 
MATERIAL and METHODS

Cell lines and cytokine stimulation
The Panc02 cell line was established from a tumor that was induced by 3-methylcholanthren in the pancreas of C57BL/6 mice and was a kind gift of Prof. Christiane Bruns, Chirurgische Klinik, LMU Munich (19). The human pancreatic adenocarcinoma cell lines PANC-1, MIAPaCa-2, and BxPC-3 cell lines were obtained from American Type Culture Collection and were used within 6 months after resuscitation (ATCC, Manassas, VA, USA). PaTu8988t cell line was obtained from Germany). IFN-α was used at concentrations of 100 IU/ml for murine and 1000 IU/ml for human cell lines (Miltenyi, Bergisch Gladbach, Germany).
siRNAs and transfection
siRNAs against TGF-β 1 , RIG-I, Puma and Noxa were designed according to published guidelines and were purchased from Eurofins MWG Operon (Ebersberg, Germany) (21). The matching 5'-triphosphate-modified siRNA was transcribed using the correlating DNA template that contained the T7 RNA polymerase promoter sequence. In vitro transcription of ppp-RNA was done using the MEGAshortscript TM T7 Kit (Ambion, Austin, Texas) according to the manufacturer's protocol (14, 15 
Protein preparation and Western blot
Tumor tissue was snap frozen in liquid nitrogen and homogenized using mortar and pestle under constant liquid nitrogen cooling. Cells were lysed (Bio-Plex Cell Lysis Kit, BioRad, Munich, Germany), protein concentrations of supernatants were analyzed by Bradford assay (BioRad) and adjusted for whole protein concentration. For Western blotting, cells were lysed in Laemmli buffer and boiled for 10 min. Cell lysates were separated using a 10% SDS-PAGE. RIG-I was 9 detected with anti-RIG-I mAb (clone ALME-1, ENZO Life Sciences GmbH, Lörrach, Germany) followed by HRP-coupled secondary antibody (Santa Cruz Biotechnology, Heidelberg, Germany). Anti-pIRF-3 mAb was from New England BioLabs (Frankfurt, Germany). Blots were visualized using ECL substrate (GE Healthcare, Munich, Germany). FACSCanto II (BD) and data analyzed using FlowJo software (Version 8.5.3, Tree Star Inc., Ashland, Oregon).
ELISA
Detection of apoptosis
Apoptosis was determined using annexin V-APC (Invitrogen, Karlsruhe, Germany) and propidium iodide staining by flow cytometry. Activation of caspase-9 in tumor cells was analyzed by flow cytometry using the caspase-9 and caspase 3/7 FLICA Kits (Immunochemistry, Biomol, Hamburg, Germany). Caspase-9 western blot was done using mouse anti-caspase-9 mAb detecting both the pro-form and active form (New England Biolabs GmbH, Frankfurt am Main, Germany). Activated caspase-9 in tumor lysates was quantified by colorimetric analysis using the Caspase-9 Activity Detection Kit (Abcam, Cambridge, UK). TUNEL staining was performed using the In Situ Cell Death Detection Kit (Roche, Mannheim, Germany) and mounted with 
Statistical analysis
Data present means + SD (in vitro data) or SEM (in vivo data). Significant differences were analyzed using two-tailed Student's t-test. Multiple comparisons were analyzed by one-way ANOVA including Bonferroni correction. Survival curves were analyzed with Mantel-Cox test.
Statistical analysis was performed using GraphPad Prism software (version 5.0a); p-values <0.05 were considered significant. 
RESULTS
Pancreatic carcinoma cells express functional RIG-I
RIG-I expression was studied in human PanIN lesions, primary pancreatic adenocarcinomas and metastases by immunohistochemistry. We found strong cytosolic staining for RIG-I in premalignant lesions and in tumor cells in 10 out of 10 specimens (suppl. Fig. 1 ).
We also assessed RIG-I expression by qRT-PCR and Western blot in various human pancreatic cancer cell lines, including PANC-1, PaTu8988t, MIAPaCa-2, IMIM-PC-1 and BxPC-3 that were cultured in the absence or presence of IFN-α. All human pancreatic cancer cell lines tested expressed basal levels of RIG-I protein that were upregulated upon IFN-α treatment (Fig. 1A) .
We next assessed RIG-I signaling in pancreatic cancer cells in response to treatment with the RIG-I ligand ppp-RNA. We observed phosphorylation of the nuclear transcription factor IRF-3 in all cell lines (Fig. 1B) . Again, RIG-I silencing confirmed the critical role of RIG-I signaling for these effects (Fig. 2D) .
Thus, the Panc02 model enabled us studying the therapeutic potential of ppp-RNAs in vivo in immune competent mice.
RIG-I signaling induces apoptosis in pancreatic carcinoma cells
In previous studies, RIG-I signaling was shown to induce apoptosis in melanoma cells via the intrinsic, caspase-9-dependent pathway involving upregulation of the pro-apoptotic BH3-only proteins Noxa and Puma (14, 15) . We next assessed whether this pro-apoptotic pathway is also active in pancreatic cancer cells. Treatment with ppp-RNA strongly induced apoptosis in both human and murine pancreatic carcinoma cells as determined by PARP cleavage (data not shown) and annexin V binding, which was strongly reduced in RIG-I silenced tumor cells (Fig. 3A and   B ). In line with activation of the intrinsic apoptosis pathway we observed activation of caspase-9 and caspases-3/7 ( Fig. 3C and D) . Moreover, ppp-RNA induced upregulation of Puma and Noxa in pancreatic cancer cells (Fig. 3E) . Interestingly, siRNA-mediated silencing of Puma significantly inhibited apoptosis induction. Together these results demonstrate that pancreatic cancer cells are sensitive to pro-apoptotic RIG-I signaling and confirm a role of pro-apoptotic BH3-only proteins in RIG-I-induced apoptosis.
Bifunctional ppp-TGF-β combines TGF-β gene silencing with RIG-I activation in vitro
To assess whether RIG-I activation and RNAi-mediated silencing of TGF-β can be combined in a single molecule, we designed a siRNA targeting TGF-β 1 and the corresponding ppp-siRNA by in vitro transcription using a DNA template of the same sequence containing the T7 RNA polymerase promoter sequence (16 (OH-TGF-β) and ppp-modified siRNA (ppp-TGF-β) reduced TGF-β to a similar extent in Panc02 cells on mRNA and protein levels (Fig. 4A) . Thus, silencing activity was not impeded by the ppp-modification. Moreover, ppp-TGF-β induced upregulation of CXCL10, IFN-β and MHC-I as well as apoptosis of Panc02 cells to a similar extent as control ppp-RNA (Fig. 4B-D) .
Of note, silencing of TGF-β with OH-TGF-β by itself had no influence on the viability of Panc02 cells. Similar results were obtained with a ppp-siRNA targeting TGF-β in human PANC-1 cells (suppl. Fig. 2) . Thus, ppp-TGF-β effectively combines RNAi-mediated TGF-β silencing with ppp-RNA-mediated RIG-I activation in pancreatic cancer cells.
Treatment of tumor-bearing mice with ppp-TGF-β leads to immune activation and TGF-β silencing in vivo
Next, we examined the immune stimulatory activity of ppp-TGF-β in the Panc02 pancreatic cancer model. Ten days after orthotopic tumor induction, mice were treated intravenously with RNAs and cytokine production was measured in serum. Injection of ppp-RNA and ppp-TGF-β induced high serum levels of CXCL10, IFN-α and moderate levels of TNF-α (Fig. 5A ). In addition, we observed a potent systemic immune activation as evidenced by a strong upregulation of CD69 expression on B cells, CD4 + and CD8 + T cells, as well as NK and NKT cells (Fig. 5B) . Of note, intermediate levels of immune activation were also observed for siRNA against TGF-β. However, these were strongly reduced in TLR7 -/-mice, indicative of a previously described off-target effect of unmodified siRNA (suppl. Fig. 3 ) (26, 27) . In contrast, immune activation in response to ppp-TGF-β treatment was not affected in mice lacking either TLR7 or TRIF (TLR3 signaling). High serum levels of TGF-β correlate with poor prognosis and resistance to therapy in pancreatic cancer patients (33) . We previously reported elevated TGF-β serum levels in mice with Panc02 tumors (34). To document the influence of Panc02 tumors on TGF-β serum levels, we analyzed serum samples on days 0, 14 and 25 after tumor induction. TGF-β serum levels were increased in tumor-bearing animals and correlated with tumor burden (Fig. 5D) . In vivo administration of both, OH-TGF-β or ppp-TGF-β significantly reduced serum TGF-β levels in mice with early and late stage pancreatic tumors (Fig. 5E) . Together, these results confirm the in vivo activity of ppp-TGF-β in regards to systemic TGF-β silencing and RIG-I activation in mice with orthotopic pancreatic cancer. 
Next, we addressed the question whether systemic treatment with ppp-TGF-β results in TGF-β silencing and RIG-I activation in pancreatic tumor tissue in vivo. Mice with orthotopic Panc02 tumors were treated with RNAs on days 12 and 14 after tumor induction, and tumors were removed 12 hours later for ex vivo analysis. Both, OH-TGF-β and ppp-TGF-β significantly reduced TGF-β on mRNA and protein levels (Fig. 6A) . Moreover, bifunctional ppp-TGF-β induced upregulation of CXCL10 and IFN-β expression in tumor tissue (Fig. 6B) (Fig. 6C) . No difference in FoxP3 expression, a marker expressed by regulatory T cells, was observed between treatment groups (Fig. 6C) .
H&E and TUNEL staining of tumor sections revealed profound tumor cell apoptosis in mice treated with ppp-TGF-β (Fig. 7A and B) , which correlated with increased caspase-9 activity in tumor lysates (Fig. 7C) . Immunohistology and FACS analysis revealed increased numbers of tumor-infiltrating CD8 + T cells and upregulation of the activation marker CD69 (Fig.   7D ). Together, these data demonstrate potent anti-tumor activity of ppp-TGF-β treatment in vivo. were 0%, 6%, 6% and 33% for OH-RNA, ppp-RNA, OH-TGF-β and ppp-TGF-β, respectively (Fig. 7E) . 
